Reference 20
Carotid Stenting
Carotid Stenting
Reference No. | Ref 20 |
| Reference Name | Carotid Stenting |
| Advisory Panels | Dr Doug Travis (Chair and MSAC member) Professor Bryant Stokes (MSAC member) Mr Lou McCallum (MSAC member) Associate Professor Richard King (MSAC member) Professor Ken Thomson (MSAC member) Dr Gishel New (co-opted Cardiologist) Associate Professor Makhan Khangure (RANZCR nominee) Mr Peter L. Field (RACS nominee) Associate Professor David Muller (CSANZ nominee) Professor Geoffrey Donnan (Neurologist) |
| Date Received by MSAC Secretariat | 6 December 2002 |
| Stage 1 - Eligibility | Eligible |
| Stage 2 - Assessment | Completed |
| Stage 3 - Formulation of Advice to the Minister | This assessment was considered by the MSAC at the 2 March 2005 meeting. MSAC found that the safety and effectiveness of carotid percutaneous transluminal angioplasty with stenting (CPTAS) neuroprotection is equivalent to carotid endarterectomy (CEA) in patients who meet the usual clinical indications for CEA. Additional effectiveness has not been demonstrated for CPTAS over CEA. Neuroprotection devices should be used for CPTAS where feasible. The unmeasured value of patient preference has been recognised. However, direct health care costs of CPTAS are higher, without a measurable improvement in outcome. CPTAS should be funded for patients who meet the criteria for CEA but are unfit for open surgery (CEA). At current costs, public funding for CPTAS is not recommended for other patient groups. |
| Stage 4 - Decision | Endorsed by the Minister for Health and Ageing on 4 July 2005 |
| Stage 5 - Implementation |  |
Page currency, Latest update: 30 March, 2009
